Aigen Investment Management, LP Blueprint Medicines Corp Transaction History

Aigen Investment Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$73.17 - $99.79 $338,338 - $461,428	4,624 New	4,624 $438,000
Q2 2023 Aug 14, 2023	BUY	$42.2 - $66.37 $364,397 - $573,104	8,635 New	8,635 $545,000
Q2 2022 Aug 02, 2022	BUY	$45.23 - $70.15 $197,383 - $306,134	4,364 Added 48.92%	13,284 $671,000
Q1 2022 May 05, 2022	BUY	$54.1 - $110.08 $482,572 - $981,913	8,920 New	8,920 $570,000
Q3 2021 Nov 12, 2021	SELL	$80.98 - $109.47 $1.16 Million - $1.57 Million	-14,314 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$82.78 - $101.0 $1.18 Million - $1.45 Million	14,314 New	14,314 $1.26 Million
Q2 2020 Aug 10, 2020	SELL	$57.09 - $79.27 $259,702 - $360,599	-4,549 Closed	0 $0
Q1 2020 May 08, 2020	BUY	$48.11 - $82.22 $200,955 - $343,432	4,177 Added 1122.85%	4,549 $266,000
Q4 2019 Feb 04, 2020	BUY	$66.73 - $82.59 $24,823 - $30,723	372 New	372 $30,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.47B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

Stay updated on Aigen Investment Management, LP with notifications on news.